Ministry of Food and Drug Safety begins investigation into hyperlipidemia treatment that Daewon Pharmaceutical is producing on consignment
김지선
stockmk2020@alphabiz.co.kr | 2023-10-13 03:07:11
[Alpha Biz=(Chicago) Reporter Kim Jisun] The Ministry of Food and Drug Safety has launched an investigation into the cause of the report that other drugs are included in the hyperlipidemia treatment "Rosuvastatin" of Dongkuk Pharmaceutical, which is being commissioned by Daewon Pharmaceutical.
According to the Ministry of Food and Drug Safety on the 12th, a report was recently received that a digestive medicine product was found in the Rosuvastatin product box. There are two packages of Rosuvastatin, 15 pills each, one of which was for stomach medicine.
Rosuvastatin, a hyperlipidemia complex of Dongkuk Pharmaceutical, is a product commissioned by Daewon Pharmaceutical at Hyangnam Plant in Hwaseong, Gyeonggi-do.
Daewon Pharmaceutical Co. said it is conducting a full investigation into the manufacturing line that produced the product on the same day and Dongkuk Pharmaceutical Co. is recalling the product.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1Samsung Electronics Labor Talks Collapse Again as Union Rejects “Industry-Leading” Compensation Proposal
- 2Korea Exchange Flags 76 Suspected Short-Selling Violations via Monitoring System
- 3Affinity Equity Partners Seeks Price Cut in Lotte Rental Deal Amid Antitrust Hurdles
- 4Naver Revises Dormant Account Policy for Mail Service to Cut Costs and Reduce Spam Traffic
- 5Court Dismisses Shareholder Derivative Suit Against DB HiTek Chairman Family Over Compensation Dispute
- 6NH Investment & Securities Cuts NAVER Target Price to KRW 320,000, Maintains ‘Buy’ on AI Growth Outlook